Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial

A phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanylhydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma. All patients had relapsed after only one prior chemotherapy regimen (CHOP — 56%; mBACOD — 28%). There were three complete and eight partial responses (overall response rate — 34%) among 32 eligible patients. The median duration of remission was 6.0 months. Severe granulocytopenia was common, with 19/32 patients (63%) suffering life-threatening, and 1/32 (3%) suffering fatal, granulocytopenia.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45311/1/10637_2004_Article_BF00170868.pd

Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study

Fifty-two patients with progressive resistant multiple myeloma were entered in this Southwest Oncology Group Phase II study, using weekly intravenous Aclacinomycin A. Of forty-three evaluable patients for response, there was one partial remission of 2 years duration and two sustained clinical improvements with 25% reduction in paraprotein. Major toxicity seen was severe myelosuppression and significant nausea and vomiting requiring dose reduction and delay of the scheduled treatment. Cardiac arrhythmia was seen in one patient. Chronic daily schedule or continuous IV infusion is recommended for future study.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45336/1/10637_2004_Article_BF00216933.pd